What factors drove the changes in Anika Therapeutics's revenue and profit?

What is Anika Therapeutics's latest dividend and current dividend yield?

What is the market's earnings forecast for Anika Therapeutics next quarter?

What were the key takeaways from Anika Therapeutics's earnings call?

What is the revenue and EPS growth rate for Anika Therapeutics year over year?

What were the key takeaways from Anika Therapeutics’s earnings call?

What guidance did Anika Therapeutics's management provide for the next earnings period?

What does Anika Therapeutics do and what are its main business segments?

- **Commercial Channel Dominance**: 22% YoY growth in Commercial Channel offsets OEM decline, driven by Integrity's 25% YoY procedure growth and international expansion.
- **Product Pipeline Progress**: Hyalofast PMA submission completed; Cingal bioequivalence study initiation on track for late 2025. Over 1 million Cingal injections globally.
- **Financial Discipline**: 12% YoY SG&A reduction and $6.9M operating cash flow highlight cost control. $15M share buyback announced.
- **Growth Catalysts**: New Integrity SKUs launching in Q4; Hyalofast FDA engagement expected; Cingal U.S. launch timeline hinges on bioequivalence study completion.

**【Management Opening Remarks】**
- Anika reported Q3 2025 revenue of $27.8 million, down 6% YoY, driven by J&J's pricing pressure in the OEM channel. Commercial Channel revenue grew 22% YoY to $12 million, offsetting OEM declines.
- The company reaffirmed its focus on cost control, with SG&A expenses down 12% YoY and operating expenses down 3%.
- A second $15 million share repurchase program was announced, reflecting capital return priorities.

**【CEO Commentary】**
- **Commercial Channel Momentum**: Integrity Implant system delivered 25% YoY growth, with 500 procedures performed in Q3 and 300 surgeon users. New SKUs for hip, knee, and ankle applications are being rolled out.
- **Regulatory Progress**: Hyalofast PMA submission completed, with Phase III FastTRACK study showing clinically meaningful improvements in pain and function. Cingal bioequivalence study initiation on track for late 2025.
- **International Expansion**: Hyalofast and Cingal achieved 21% YoY growth in international OA Pain Management, with Cingal surpassing 1 million injections globally.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Commercial Channel ($12M, +22% YoY) offset OEM Channel decline (-20% YoY) due to J&J pricing pressure. Monovisc unit volume up 11% YoY, but average price down 17%.
- **Gross Margin**: 56% in Q3, down 10ppt YoY due to lower J&J sales, but up 5ppt sequentially from production recovery.
- **Operating Expenses**: Total OpEx $18.8M (-3% YoY), with R&D up 17% due to Cingal pre-filing costs. Adjusted EBITDA $0.9M, breakeven vs. prior guidance.
- **Cash Flow**: Operating cash flow $6.9M (+38% YoY), with $58M cash on hand and no debt.

**【Q&A Highlights】**
- **Integrity Growth Strategy**: Equal focus on new surgeon training and existing surgeon adoption, with 60% of users performing multiple cases. Q4 SKUs expansion expected to accelerate adoption.
- **Cingal Timeline**: Bioequivalence study start by end-2025, with NDA filing dependent on study completion. Toxicity study completion in Q1 2026.
- **Capital Allocation**: Prioritize internal investments (e.g., Integrity, Hyalofast) > CapEx > share buybacks. No M&A plans.
- **Production Issues**: Q3 disruptions resolved, with capacity restored by year-end. Gross margin expected to stabilize near 55-60% range, excluding J&J pricing volatility.

ANIK

ANIK fundamentals

You can ask Aime